TG Therapeutics focuses on developing treatments for B-cell mediated diseases. They provide BRIUMVI for relapsing multiple sclerosis treatment. Their pipeline includes Umbralisib for lymphoma and TG-1701/TG-1801, orally available BTK inhibitors. The company has license agreements with LFB Biotechnologies, GTC Biotherapeutics, and others for umbralisib development. They also have a collaboration agreement with Checkpoint Therapeutics for anti-PD-L1 and anti-GITR antibody research programs. TG Therapeutics was incorporated in 1993 and is based in Morrisville, North Carolina. The company has a range of investigational medicines in its research pipeline.
Indicator | Value |
---|---|
PER | 247.1 |
EV/EBITDA | 117.3 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 1.5 |